UniQuest, the main research commercialisation company of the University of Queensland, has facilitated a strategic research collaboration agreement with Janssen-Cilag Pty Ltd in Australia, one of the Janssen pharmaceutical companies, to develop a promising treatment for rheumatoid arthritis.

Under the agreement, Dendright Pty Ltd will receive an upfront seed grant to fund pre-clinical development of its treatment for rheumatoid arthritis . Dendright remains wholly owned by UniQuest. No other terms of the deal were disclosed.

The seed grant will help Professor Ranjeny Thomas and her team at the UQ Diamantina Institute pursue a new treatment for RA, which may also apply to other autoimmune diseases such as type 1 diabetes and multiple sclerosis.

In 2011, Professor Thomas was a plenary speaker at the prestigious American College of Rheumatology Conference in Chicago and a finalist in the Health category of the Australian Innovation Challenge Awards for her research towards a vaccine for RA.


More information is at www.uniquest.com.au/portfolio/dendright-pty-ltd